Mode
Text Size
Log in / Sign up
N/A N=175 Randomized Single-blind Treatment

Safety and Effectiveness of Restylane Lyft With Lidocaine for Augmentation of the Chin Region to Improve the Chin Profile

Chin Augmentation · Chin Retrusion

Enrolled (actual)
175
Serious AEs
1.2%
Results posted
May 2026
Primary outcome: Primary: Change From Baseline in the Blinded Evaluators' Live Assessment Using the Galderma Chin Retrusion Scale (GCRS) at Month 3 — -0.94; -1.02 score on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Restylane Lyft with Lidocaine (Device); Juvederm Voluma XC (Device)
Age
Adult, Older Adult · 22+ yrs
Sex
All
Sponsor
Galderma R&D
Primary completion
Nov 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
Change From Baseline in the Blinded Evaluators' Live Assessment Using the Galderma Chin Retrusion Scale (GCRS) at Month 3
-0.94; -1.02
SECONDARY
Responder Rate Based on the Blinded Evaluator's Live Assessment Using the GCRS at Months 6, 9, and 12
75.5; 80.0; 69.1; 79.2; 69.7; 77.8

Summary

The primary objective of the study was to demonstrate non-inferiority of Restylane Lyft with Lidocaine versus a comparator-control for augmentation of the chin region to improve the chin profile.

Eligibility Criteria

Inclusion Criteria

  • Males or non-pregnant, non-breastfeeding females, 22 years of age or older
  • Intent to receive treatment for augmentation and correction of retrusion in the chin region.

Exclusion Criteria

  • Known/previous allergy of hypersensitivity to any injectable hyaluronic acid (HA) gel or gram-positive bacterial proteins.
  • Known/previous allergy or hypersensitivity to local anesthetics, e.g., lidocaine or other amide-type anesthetics.
  • Previous or present multiple severe allergies or severe allergies, such as manifested by anaphylaxis or angioedema or family history of angioedema.
  • Previous facial surgery (including facial aesthetic surgery and liposuction), below the level of the horizontal line from the subnasale.
  • Any previous aesthetic procedures or implants
  • Presence of any disease or lesion near or on the area to be treated.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05777759). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search